Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells

Anlotinib, a multitarget tyrosine kinase inhibitor, is effective as a third-line treatment against non-small cell lung cancer (NSCLC). However, acquired resistance occurs during its administration. To understand the molecular mechanisms of anlotinib resistance, we characterized chromatin accessibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Le-le, Lu, Jun, Liu, Rui-qi, Hu, Min-juan, Zhao, Yi-ming, Tan, Sheng, Wang, Shu-yuan, Zhang, Bo, Nie, Wei, Dong, Yu, Zhong, Hua, Zhang, Wei, Zhao, Xiao-dong, Han, Bao-hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608858/
https://www.ncbi.nlm.nih.gov/pubmed/32415222
http://dx.doi.org/10.1038/s41401-020-0421-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608858/
https://www.ncbi.nlm.nih.gov/pubmed/32415222
http://dx.doi.org/10.1038/s41401-020-0421-7

Ejemplares similares